Day-100 landmark analysis of cGVHD occurrence at 1 year by day-100 biomarker thresholds for the overall cohort and by age group
| Marker∗ . | HR (95% CI) . | P value . | 1-y cumulative incidence of cGVHD, % (95% CI) . | |
|---|---|---|---|---|
| CXCL9 | <12 ng/mL | ≥12 ng/mL | ||
| Overall | 2.90 (1.46-5.79) | .002 | 28.5 (22.9-34.3) | 58.3 (28.7-79.2) |
| ≤10 y | 3.77 (0.89-15.9) | .07 | 22.9 (15.2-21.6) | 50.0 (2.9-87.3) |
| >10 y | 2.37 (1.08-5.21) | .03 | 42.8 (33.7-51.6) | 61.9 (25.2-84.6) |
| IL1RL1 | <18 ng/mL | ≥18 ng/mL | ||
| Overall | 2.36 (1.52-3.67) | <.001 | 19.5 (13.2-26.7) | 41.1 (32.4-49.7) |
| ≤10 y | 2.35 (1.08-5.12) | .03 | 14.9 (7.6-24.5) | 30.2 (17.5-43.9) |
| >10 y | 2.09 (1.22-3.59) | .01 | 24.3 (14.6-35.3) | 47.1 (35.7-57.7) |
| REG3α | <50 ng/mL | ≥50 ng/mL | ||
| Overall | 1.80 (1.18-2.74) | .01 | 22.6 (16.1-29.8) | 39.4% (30.4-48.3) |
| ≤10 y | 1.86 (0.86-4.03) | .11 | 14.7% (7.5-24.2) | 30.2% (17.6-43.9) |
| >10 y | 1.71 (1.03-2.82) | .04 | 29.3% (19.5-39.8) | 45.7% (33.4-57.1) |
| MMP3 | <9 ng/mL | ≥9 ng/mL | ||
| Overall | 2.20 (1.43-3.39) | <.001 | 19.6% (13.5-26.5) | 42.1% (33.1-50.8) |
| ≤10 y | 1.33 (0.59-2.97) | .49 | 18.7% (11.0-28.1) | 26.7% (13.1-42.4) |
| >10 y | 2.36 (1.33-4.16) | .003 | 20.5% (11.5-31.4) | 48.2% (37.1-58.5) |
| DKK3 | <48 ng/mL | ≥48 ng/mL | ||
| Overall | 2.28 (1.44-3.61) | <.001 | 20.7 (14.5-27.7) | 45.6 (33.7-56.7) |
| ≤10 y | 2.39 (1.05-5.42) | .04 | 15.0 (7.6-24.6) | 36.3 (19.4-53.5) |
| >10 y | 2.10 (1.20-3.66) | .01 | 25.8 (16.5-36.1) | 51.6 (35.6-65.5) |
| sCD163 | <620 ng/mL | ≥620 ng/mL | ||
| Overall | 1.33 (0.83-2.15) | .24 | 27.4 (20.5-34.9) | 32.5 (21.7-43.6) |
| ≤10 y | 0.69 (0.26-1.86) | .47 | 22.9 (13.8-33.4) | 18.2 (6.4-34.7) |
| >10 y | 1.74 (0.99-3.05) | .06 | 31.5 (21.4-42.0) | 42.2 (26.7-57.0) |
| Marker∗ . | HR (95% CI) . | P value . | 1-y cumulative incidence of cGVHD, % (95% CI) . | |
|---|---|---|---|---|
| CXCL9 | <12 ng/mL | ≥12 ng/mL | ||
| Overall | 2.90 (1.46-5.79) | .002 | 28.5 (22.9-34.3) | 58.3 (28.7-79.2) |
| ≤10 y | 3.77 (0.89-15.9) | .07 | 22.9 (15.2-21.6) | 50.0 (2.9-87.3) |
| >10 y | 2.37 (1.08-5.21) | .03 | 42.8 (33.7-51.6) | 61.9 (25.2-84.6) |
| IL1RL1 | <18 ng/mL | ≥18 ng/mL | ||
| Overall | 2.36 (1.52-3.67) | <.001 | 19.5 (13.2-26.7) | 41.1 (32.4-49.7) |
| ≤10 y | 2.35 (1.08-5.12) | .03 | 14.9 (7.6-24.5) | 30.2 (17.5-43.9) |
| >10 y | 2.09 (1.22-3.59) | .01 | 24.3 (14.6-35.3) | 47.1 (35.7-57.7) |
| REG3α | <50 ng/mL | ≥50 ng/mL | ||
| Overall | 1.80 (1.18-2.74) | .01 | 22.6 (16.1-29.8) | 39.4% (30.4-48.3) |
| ≤10 y | 1.86 (0.86-4.03) | .11 | 14.7% (7.5-24.2) | 30.2% (17.6-43.9) |
| >10 y | 1.71 (1.03-2.82) | .04 | 29.3% (19.5-39.8) | 45.7% (33.4-57.1) |
| MMP3 | <9 ng/mL | ≥9 ng/mL | ||
| Overall | 2.20 (1.43-3.39) | <.001 | 19.6% (13.5-26.5) | 42.1% (33.1-50.8) |
| ≤10 y | 1.33 (0.59-2.97) | .49 | 18.7% (11.0-28.1) | 26.7% (13.1-42.4) |
| >10 y | 2.36 (1.33-4.16) | .003 | 20.5% (11.5-31.4) | 48.2% (37.1-58.5) |
| DKK3 | <48 ng/mL | ≥48 ng/mL | ||
| Overall | 2.28 (1.44-3.61) | <.001 | 20.7 (14.5-27.7) | 45.6 (33.7-56.7) |
| ≤10 y | 2.39 (1.05-5.42) | .04 | 15.0 (7.6-24.6) | 36.3 (19.4-53.5) |
| >10 y | 2.10 (1.20-3.66) | .01 | 25.8 (16.5-36.1) | 51.6 (35.6-65.5) |
| sCD163 | <620 ng/mL | ≥620 ng/mL | ||
| Overall | 1.33 (0.83-2.15) | .24 | 27.4 (20.5-34.9) | 32.5 (21.7-43.6) |
| ≤10 y | 0.69 (0.26-1.86) | .47 | 22.9 (13.8-33.4) | 18.2 (6.4-34.7) |
| >10 y | 1.74 (0.99-3.05) | .06 | 31.5 (21.4-42.0) | 42.2 (26.7-57.0) |
Sample sizes for models were overall, N = 291; ≤10 years, n = 123; >10 years, n = 168, with the exception of models for DKK3 and sCD163 in which sample sizes were overall, N = 243; ≤10 years, n = 104; >10 years, n = 139.
CI, confidence interval.
Markers dichotomized at selected thresholds.